ANI Pharmaceuticals
ANIP
121 hedge funds and large institutions have $276M invested in ANI Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 48 increasing their positions, 35 reducing their positions, and 22 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 35
37% more call options, than puts
Call options by funds: $6.29M | Put options by funds: $4.6M
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
2% less funds holding
Funds holding: 123 → 121 (-2)
32% less capital invested
Capital invested by funds: $403M → $276M (-$127M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Senzar Asset Management
New York
|
+$15.4M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$13.6M |
| 3 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$10.8M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.53M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$17.5M |
| 2 |
TCM
Timpani Capital Management
Milwaukee,
Wisconsin
|
-$5.13M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.18M |
| 4 |
TA
Teachers Advisors
New York
|
-$3.6M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$3.46M |
ANIP Hedge Fund Activity: Q3 2015 in Review
121 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2015, worth a combined $276M — down 32% from $403M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ANIP and 21 opened new positions — a net loss of 1 holder — while 35 trimmed existing stakes and 48 added.
The largest buyer was Senzar Asset Management, opening a new position worth an estimated $15.4M. The largest seller was Perceptive Advisors, cutting an estimated $17.5M.
- 121 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2015, down from 123 in Q2 2015.
- Funds reported $276M of ANI Pharmaceuticals stock for Q3 2015, down 32% quarter-over-quarter.
- 21 funds opened new ANI Pharmaceuticals positions in Q3 2015 and 22 closed out, a net change of -1 holder.
- The largest ANI Pharmaceuticals buyer in Q3 2015 was Senzar Asset Management, an estimated $15.4M added.
- The largest ANI Pharmaceuticals seller in Q3 2015 was Perceptive Advisors, an estimated $17.5M sold.
Based on aggregated 13F filings for Q3 2015.